Amicus Therapeutics, a clinical-stage biotech developing a treatment for genetic diseases, has priced its 5 million share offering at $15, the midpoint of its proposed range. Amicus' three drug candidates are based on its orally-administered chaperone technology. Morgan Stanley and Merrill Lynch managed the deal; the stock is expected to begin trading on the NASDAQ this morning under the ticker FOLD.
